#### Natural Product Analogues

### Synthetic Studies on Thiostrepton: Construction of Thiostrepton Analogues with the Thiazoline-Containing Macrocycle\*\*

### K. C. Nicolaou,\* Marta Nevalainen, Mark Zak, Stephan Bulat, Marco Bella, and Brian S. Safina

Thiostrepton (1, Scheme 1)<sup>[1]</sup> is a highly complex thiopeptide antibiotic endowed with an unusual molecular architecture and a mode of action that involves RNA binding. As part of our program directed towards the total synthesis of this unique natural product, we have already reported synthetic approaches to both its dehydropiperidine domain<sup>[2]</sup> and its segment corresponding to the quinaldic acid macrocycle.<sup>[3]</sup> Herein we disclose further advances that pave the way for an

[*] Prof. Dr. K. C. Nicolaou, Dr. M. Nevalainen, M. Zak, Dr. S. Bula Dr. M. Bella, B. S. Safina
Department of Chemistry and
The Skaggs Institute for Chemical Biology
The Scripps Research Institute
10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)
Fax: (+1) 858-784-2469
E-mail: kcn@scripps.edu
and
Department of Chemistry and Biochemistry
University of California, San Diego
9500 Gilman Drive, La Jolla, CA 92093 (USA)

[\*\*] We thank Dr. D. H. Huang, Dr. G. Siuzdak, and Dr. R. Chadha for NMR spectroscopic, mass spectrometric, and X-ray crystallographic assistance, respectively. Financial support for this work was provided by The Skaggs Institute for Chemical Biology, the National Institutes of Health (USA), fellowships from The Academy of Finland (to M.N.), The Skaggs Institute for Research (to M.Z.), and Bayer AG (to S.B.), and grants from Abbott, Amgen, ArrayBiopharma, Boehringer-Ingelheim, Glaxo, Hoffmann-LaRoche, DuPont, Merck, Novartis, Pfizer, and Schering Plough. eventual total synthesis of 1 and its analogues by addressing the remaining challenges posed by the imposing and sensitive structure of the molecule. Specifically, we describe: 1) the construction of the thiazoline 7 and thiazole 8 fragments, 2) the synthesis of the dehydropyrrolidine isomer 4 of the dehydropiperidine domain and its 5S,6S diastereoisomer 4', and 3) the assembly of these fragments into thiostrepton analogues 2 and 3, which lack only the quinaldic acid macrocycle and differ from thiostrepton (1) at the iminecontaining ring core (Scheme 1).

We begin with our previously reported<sup>[2]</sup> biomimetically inspired aza-Diels-Alder dimerization, which delivered the dehydropiperidine domain 9 (5R,6R-diastereoisomer, Scheme 2) as a 1:1 mixture with its 5S,6S-diastereoisomer 9' (not shown). In solution, these dehydropiperidine compounds (9 and 9') rearrange into their dehydropyrrolidine counterparts 4 and 4', respectively, reaching an equilibrium via aminal 10 and 10'.<sup>[4]</sup> The six-membered ring imine 9 (and 9') can be selectively reduced with NaCNBH<sub>3</sub> under acidic conditions over its five-membered counterpart (4 and 4'), presumably due to less steric hindrance around the C=N bond, to render diamine 11 (and 11'), as we already reported.<sup>[2]</sup> However, under standard amide bond-forming conditions (EDC, HOAt) with alloc-L-Ala-OH (5, Scheme 1), the five-membered ring imine 4 (and 4') is selectively captured, leading to compound 13 (and 13'), obtained as a mixture of 5*R*,6*R*- and 5S,6S-diastereoisomers, which were chromatographically separated (72% combined yield). On the other hand, diamine 11 (and 11') can also be coupled with alloc-L-Ala-OH (5) (HOAt, HATU, EtNiPr<sub>2</sub>) predominantly at the primary amine site (2:1 ratio of regioisomers) yielding, upon oxidation with tBuOCl and base-induced elimination of HCl from the resulting chloroamine, the dehydropiperidine peptide 12 (and 12') in 21 % overall yield (from 9 and 9'). While attempting to optimize this route to 12 (and 12'), we opted to construct analogues 2 and 3 utilizing the more available dehydropyrrolidine intermediates 13 and 13' with the dual aim of scouting the ground for the total synthesis of thiostrepton (1) and to produce novel thiostrepton analogues for biological evaluation.

With ample quantities of the central core 13 and its 55,65 diastereoisomer (13') in hand, we proceeded to construct the remaining key building blocks 6-8 (Scheme 1). Scheme 3 outlines the synthesis of the thiazole amino acid equivalent 8, starting from angelic acid methyl ester (14). Thus, sequential conversion of commercially available 14 into its acid 15 (90% yield), acid chloride 16, and (-)-menthyl ester 17 (70% over two steps) allowed a diastereoselective dihydroxylation with AD-mix- $\beta$  and MeSO<sub>2</sub>NH<sub>2</sub>, leading to diol **18**<sup>[5]</sup> (90% yield, d.r. 90:10). The latter compound, 18, was further protected as acetonide 19 (100% yield) and then reduced with DIBAL-H (90%) to alcohol 20. In a remarkable one-pot sequence, alcohol 20 was oxidized with DMP; the aldehyde obtained in this manner was engaged in situ with benzylamine in the presence of Yb(OTf)<sub>3</sub><sup>[6]</sup> and molecular sieves (4 Å), and the resulting imine was treated with trimethylsilyl cyanide<sup>[7]</sup> to furnish Strecker addition product 21 in 90% overall yield. To our delight, not only did this sequence produce virtually a single stereoisomer (d.r. > 95:5 according to <sup>1</sup>H NMR spec-



**Scheme 1.** Structures of thiostrepton (1) and analogues 2 and 3, and retrosynthetic analysis of the latter two compounds to building blocks 4–8 and 4'. Alloc = allyloxycarbonyl; Boc = *tert*-butoxycarbonyl; TBS = *tert*-butyldimethylsilyl; TES = triethylsilyl.

troscopic analysis), but, also, the obtained material possessed the correct stereochemistry, as proven by X-ray crystallographic analysis of a subsequent intermediate (i.e. **25**, see ORTEP drawing, Scheme 3). Hydrogenolysis of the benzyl group of **21** in the presence of  $(Boc)_2O$  led to Boc derivative **22** in 75 % yield. Treatment of **22** with H<sub>2</sub>S in the presence of Et<sub>3</sub>N in a sealed tube afforded thioamide **23** (90%), which was then treated with ethyl bromopyruvate under standard Hantzsch conditions<sup>[8]</sup> to afford thiazole **24** in 82% yield. For reasons of protecting-group compatibility in subsequent steps, we moved to modify the diol and amine functionalities within the latter substrate by first removing the groups guarding

## Communications



Scheme 2. Construction of dehydropiperidine and dehydropyrrolidine systems 12 and 13. Reagents and conditions: a) 1) Alloc-L-Ala-OH (5) (1.2 equiv), HOAt (1.3 equiv), EDC (1.3 equiv), DMF, 25 °C, 12 h; 2) separation of diastereomers (silica gel, Et<sub>2</sub>O/toluene (60–80%), then EtOAc/ hexane(90%)), 72% combined yield; b) NaCNBH<sub>3</sub> (2.0 equiv), AcOH/EtOH (1:4), 0 °C, 1 h, 50%; c) Alloc-L-Ala-OH (5) (1.1 equiv), HOAt (1.1 equiv), EtN*i*Pr<sub>2</sub> (3.0 equiv), DMF, 25 °C, 2 h, 60%; d) *t*BuOCl (1.2 equiv), THF, -78 °C, 0.5 h, 4-DMAP (0.2 equiv), Et<sub>3</sub>N (2.0 equiv), 25 °C, 10 min, 70%. HATU = *O*-(7-azabenzotriazol-1-yl)-*N*,*N*,*N*,*N*,'A'-tetramethyluronium hexafluorophosphate; EDC = 1-ethyl- (3-dimethylaminopropyl)carbodiimide hydrochloride; DMF = *N*,*N*-dimethylformamide; 4-DMAP = 4-dimethylaminopyridine; HOAt = 1-hydroxy-7- azabenzotriazole. Compounds 4, 9–13 are accompanied (ca. 1:1) by their 55,65 diastereoisomers (4', 9'–13', respectively, structures not shown).

them and then remasking them in a different way. Thus, **24** was exposed to NaOEt in ethanol, furnishing the crystalline derivative **25** by removal of the trifluoroacetate group in quantitative yield. The latter compound (**25**) was then treated with TFA to furnish amino diol **26**, which was selectively converted into monosilyl ether **27** by reaction with TBSCl in the presence of Et<sub>3</sub>N (81% yield over two steps). Finally, conversion of the amine within **27** into the corresponding azide (**28**) through the diazo-transfer procedure,<sup>[9]</sup> followed by basic hydrolysis of the ethyl ester, afforded the targeted building block **8** in 78% overall yield.

The synthesis of thiazoline moiety **7**, a structural element unique to thiostrepton—the other peptide antibiotics of the same family contain a thiazole instead—was carried out as summarized in Scheme 4 (p. 3422). Coupling of commercially available Fmoc-threonine (**29**) with D-serine methyl ester under standard conditions (EDC, HOBt,  $Et_3N$ ) gave dipeptide **30** in 70% yield. Silylation of both hydroxy groups of **30** (81% yield), followed by thiocarbonylation with Lawesson's reagent, gave thioamide **32** (79% yield) via bis-TES-derivative **31**. The next requisite amino acid equivalent, compound **37**, was prepared from TBS-protected Boc-L-threonine methyl ester (**34**)<sup>[10]</sup> by first removing the Boc group with TFA, and then converting the corresponding primary amine of **35** into an azide functionality through the above-mentioned diazo-transfer procedure to provide **36** (72% over two steps). Hydrolysis of the ester provided acid **37** (93% yield), which was then coupled under standard conditions (HATU, HOAt, Et<sub>3</sub>N) with amine **33** generated from its Fmoc derivative **32** through the action of Et<sub>2</sub>NH to afford tripeptide surrogate **38** (75% from **32**). The primary TES group of **38** was selectively cleaved with THF/AcOH/H<sub>2</sub>O (3:1:1) at 25°C to furnish alcohol **39**, which upon exposure to DAST<sup>[11]</sup> led smoothly to the expected thiazoline **40** (90% yield). The final step required to complete the synthesis of **7** was the Staudinger reaction<sup>[12]</sup> of the azide to form the amino group, a transformation smoothly effected with trimethylphosphane and water (92% yield).

Scheme 5 (p. 3422) depicts the synthesis of the dipeptide equivalent to the top side chain of thiostrepton, bisseleno dipeptide 6. This intermediate was synthesized from known L-serine derivative  $41^{[13]}$  by first generating the amino seleno-amide 43 (via 42) and then coupling the two (41 and 43) under the influence of EDC and HOBt (58% over two steps), followed by removal of the remaining Boc group with TFA (95% yield).

The assembly of the targeted thiostrepton analogue 2 from the five-membered ring imine core 13 and the described





Scheme 3. Synthesis of thiazole amino acid equivalent 8. Reagents and conditions: a) LiOH (0.7 equiv), MeOH/H<sub>2</sub>O (1:1), reflux, 4 h, 90%; b) KOH (1.0 equiv), (COCl)<sub>2</sub> (5.0 equiv), Et<sub>2</sub>O, DMF (cat.), 2 h; c) (-). menthol (0.7 equiv), Et<sub>2</sub>O, 25 °C, 48 h, 70% (two steps); d) AD-mix-β (1.5 equiv), MeSO<sub>2</sub>NH<sub>2</sub> (1.0 equiv), *t*BuOH/H<sub>2</sub>O (1:1), 0°C, 24 h, 90%, 90:10 d.r.; e) Me<sub>2</sub>C(OMe)<sub>2</sub> (22.0 equiv), TsOH (0.05 equiv), 25 °C, 1 h, 100%; f) DIBAL-H (2.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, -78°C, 2 h, 90%; g) DMP (1.1 equiv), NaHCO<sub>3</sub> (2.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 3 h; h) BnNH<sub>2</sub> (1.2 equiv), Yb(OTf)<sub>3</sub> (0.2 equiv), molecular sieves (4 Å), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 2 h; i) TMSCN (2.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 3 h, 90% (three steps), >95:5 d.r.; j) (Boc)<sub>2</sub>O (1.1 equiv), EtOAc, 20% Pd/Pd(OH)<sub>2</sub> (0.2 equiv), H<sub>2</sub>, 25 °C, 12 h, 75%; k) H<sub>2</sub>S, Et<sub>3</sub>N/EtOH/pyridine (1.7:1.7:1), sealed tube, 25 °C, 12 h, 90%; l) BrCH<sub>2</sub>COCO<sub>2</sub>Et (3.0 equiv), NaHCO<sub>3</sub> (8.0 equiv), DME, 25 °C, 24 h, 82%; m) TFAA (4.0 equiv), pyridine (9.0 equiv), 0°C, 1 h, 82% (two steps); n) NaOEt (1.0 equiv), EtOH, 0°C, 1 h, 100%; o) TFA/EtOH/CH<sub>2</sub>Cl<sub>2</sub> (1:1:1), 0-25 °C, 4 h; p) TBSCI (2.2 equiv), Et<sub>3</sub>N (3.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0-25 °C, 12 h, 81 % (two steps); q) TfN<sub>3</sub> (3.0 equiv), Et<sub>3</sub>N (3.0 equiv), CuSO<sub>4</sub> (0.05 equiv), MeOH/H<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub> (3.3:1:1), 25 °C, 12 h, 82%; r) LiOH (3.0 equiv), THF/H<sub>2</sub>O (1:1), 0°C, 2 h, 95%. DMP=Dess-Martin periodinane; DIBAL-H = diisobutylaluminum hydride; TMS = trimethylsilyl; DME = ethylene glycol dimethyl ether; TFAA = trifluoroacetic anhydride; TFA = trifluoroacetic acid; Ts = p-toluenesulfonyl; Tf = trifluoromethanesulfonyl.

building blocks 6-8 proceeded as shown in Scheme 6 (p. 3423). Thus, the less polar isomer 13 (5R,6R) was treated with TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1) to afford amino alcohol 45 while its more polar diastereoisomer 13' (5S,6S, not shown) led, under the same conditions, to the corresponding amino alcohol 45' (5S,6S, see Figure 1). Crystallization experiments with these diastereoisomers provided a crystalline derivative of the more polar compound (45') with L-tartaric acid, whose X-ray crystallographic analysis revealed its absolute configuration (see ORTEP drawing, Figure 1), and, by extension, that of diastereoisomer 45. Amino alcohol 45 was then coupled with thiazole amino diol 8 in the presence of HATU and HOAt to afford peptide 46 (65% yield over two steps, Scheme 6). The next problematic issue in the sequence was the differentiation between the two ethyl esters within compound 46. As a result of the conjugation of one of the thiazole moieties with the imine functionality of 46, we expected the ester on that thiazole to be more electrondeficient, and, therefore, more prone to hydrolysis. Gratifyingly, we found that, indeed, treatment of the latter compound, 46, with 1 equivalent of lithium hydroxide in a 3:1:1 mixture of THF/EtOH/H<sub>2</sub>O generated, regioselectively, a single carboxylic acid in 52% yield (plus 28% recovered starting material). More significantly,



**Figure 1.** ORTEP drawing of **45**′ (45,55) obtained by X-ray crystallographic analysis of its 1:1 salt with L-tartaric acid (L-tartaric acid not shown).

Angew. Chem. Int. Ed. 2003, 42, 3418-3424

25

ORTEP drawing of 25

# Communications



**Scheme 4.** Synthesis of thiazoline moiety **7**. Reagents and conditions: a) D-Ser-OMe-HCl (1.0 equiv), Et<sub>3</sub>N (3.0 equiv), HOBt (1.2 equiv), EDC (1.2 equiv),  $CH_2Cl_2$ , 25 °C, 2 h, 70%; b) TESCl (2.2 equiv), imidazole (3.0 equiv),  $CH_2Cl_2$ , 25 °C, 12 h, 81%; c) Lawesson's reagent (0.55 equiv), benzene, reflux, 2 h, 79%; d) Et<sub>2</sub>NH (6.5 equiv), DMF, 25 °C; e) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1), 25 °C, 2 h; f) TfN<sub>3</sub> (3.0 equiv), Et<sub>3</sub>N (3.0 equiv), CuSO<sub>4</sub> (0.05 equiv), MeOH/H<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub> (3.3:1:1), 25 °C, 14 h, 72% (two steps); g) LiOH (1.0 equiv), THF/H<sub>2</sub>O (1:1), 0 °C, 3 h, 93%; h) HATU (1.1 equiv), HOAt (1.1 equiv), Et<sub>3</sub>N (2.0 equiv), DMF, 25 °C, 12 h, 75% (two steps from 32); i) THF/AcOH/H<sub>2</sub>O (3:1:1), 25 °C, 12 h, 75% (based on 35% recovered **38**); j) DAST (1.2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 20 min, 90%; k) Me<sub>3</sub>P (3.0 equiv), THF/H<sub>2</sub>O (20:1), 0 °C, 1 h, 92%. HOBt = 1-hydroxybenzotriazole hydrate; DAST = diethylaminosulfur trifluoride; Fmoc = fluorenylmethoxycarbonyl.



**Scheme 5.** Synthesis of side-chain precursor **6.** Reagents and conditions: a) ethyl chloroformate (1.05 equiv), NH<sub>4</sub>OH (30 equiv), EtN*i*Pr<sub>2</sub> (1.05 equiv), THF, 0–25 °C, 1 h, 89%; b) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1), 0 °C, 1 h; c) **41**, HOBt (1.1 equiv), EDC (1.1 equiv), EtN*i*Pr<sub>2</sub> (1.5 equiv), DMF, 25 °C, 5 h, 58% (two steps); d) TFA, CH<sub>2</sub>Cl<sub>2</sub> (1:1), 0 °C, 1 h, 95%.

extensive NMR studies revealed that carboxylic acid 47 was, in fact, the product of this hydrolysis reaction. The remaining ethyl ester of compound 47 was then transesterified to a methyl ester (MeONa/MeOH, 90% yield), and the carboxylic acid function of resulting 48 was coupled to side-chain precursor 6 (HATU, HOAt) to afford tetrapeptide 49 in 83% yield. The inserted transesterification step was necessary to avoid subsequent complications that arose when attempts were made to hydrolyze the more robust ethyl ester, leading to elimination of the rather labile PhSe residues and side reactions thereof. In contrast, the methyl ester of 49 could be cleaved with trimethyltin hydroxide in refluxing dichloroethane (85% yield), conditions which avoided the loss of the selenium moieties otherwise observed in the presence of other reagents, that is, lithium hydroxide. The resulting acid 50 was then coupled to thiazoline segment 7 at 0°C (HATU, of the targeted molecule paid dividends in that treatment of the bisseleno derivative **55** with *t*BuOOH at ambient temperature resulted in the smooth formation of the five-membered imine analogue **2** of thiostrepton (**1**), lacking only the macrocycle that contains the quinaldic acid group. It should be stressed that the introduction of the last two double bonds into thiostrepton-like structures was proven to be a real challenge owing to the unusual sensitivity of the resulting dehydroamino acids.<sup>[17]</sup> Thiostrepton analogue **3** (Scheme 1) was synthesized from **4**' via **45**' by an analogous route to that described for **2**, and in similar yields (see Table 1).

Preliminary biological screening<sup>[18]</sup> with 2 and 3 indicated the lack of any significant antibacterial activity as compared to 1, suggesting, perhaps, the importance of both the sixmembered ring imine and the quinaldic acid motifs of thiostrepton for the recognition of its biological targets.

HOAt) to afford product 51 in

75% yield. The obligatory low-

employed in this coupling reac-

tion were necessary to avoid

premature elimination of the

OTES group, which would lead to the conjugated thiazoline

system (see structure 2). Subse-

quent Staudinger reduction of

the azide group within  $51 (Me_3P,$ 

H<sub>2</sub>O), followed by Me<sub>3</sub>SnOHinduced methyl ester hydrolysis,

led to amino acid 53 via amino

ester **52**. Remarkably, the stereochemical integrity of the sen-

sitive thiazoline moiety was pre-

served in the hydrolysis,<sup>[14]</sup> sug-

gesting that this Me<sub>3</sub>SnOHmediated non-acidolytic and

non-nucleophilic hydrolysis<sup>[15]</sup>

could be a general mild method

for the benign cleavage of esters

within labile substrates. The key

macrolactamization of amino

acid 53 was smoothly effected

by exposure to HATU and

HOAt (0.3 mm concentration),

leading to macrolactam 54 in 51% overall yield from 51. Critically, exposure of 54 to  $3 \text{ HF} \cdot \text{Et}_3 \text{N}$  in THF at room tem-

perature resulted in the cleavage

of the two TBS groups, with

antiperiplanar elimination of

the OTES moiety, furnishing

the desired conjugated thiazo-

line system 55.<sup>[16]</sup> Finally, the

choice of the PhSe groups as

potential progenitors of the olefinic bonds of the top side chain

base-promoted

concomitant

temperature

conditions



*Scheme 6.* Synthesis of the thiazoline macrocyclic system **2**. Reagents and conditions: a) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1), 25 °C, 2 h; b) **8** (1.0 equiv), EtNiPr<sub>2</sub> (3.0 equiv), HOAt (1.1 equiv), HATU (1.1 equiv), DMF, 25 °C, 12 h, 65% (two steps); c) LiOH (1.0 equiv), THF/EtOH/H<sub>2</sub>O (3:1:1), 0 °C, 1.5 h, 52% (28% recovered **46**); d) NaOMe (2.0 equiv), MeOH, 0 °C, 1 h, 90%; e) **6** (1.1 equiv), HOAt (1.2 equiv), HATU (1.2 equiv), DMF, 25 °C, 5 h, 83%; f) Me<sub>3</sub>SnOH (13.0 equiv), 1,2-dichloroethane, reflux, 4 h, 85%; g) **7** (1.1 equiv), HOAt (1.2 equiv), HATU (1.2 equiv), DMF, 0 °C, 15 min, 75%; h) Me<sub>3</sub>P (3.0 equiv), THF/H<sub>2</sub>O (20:1), 0 °C, 30 min; i) Me<sub>3</sub>SnOH (10.0 equiv), reflux, 1 h; j) HOAt (4.0 equiv), HATU (4.0 equiv), DMF (0.3 mM), 25 °C, 12 h, 51% (three steps); k) (HF)<sub>3</sub>·Et<sub>3</sub>N (30.0 equiv), THF, 25 °C, 48 h, 50%; l) *t*BuOOH (5 м in decane, 20.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 3 h, 60%.

Angew. Chem. Int. Ed. 2003, 42, 3418-3424

www.angewandte.org

# Communications

Table 1: Selected data for compounds 2 and 3.

**2**:  $R_{\rm f} = 0.32$  (silica gel, CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 9:1); [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -104.7 (c = 0.20, MeOH); IR (film):  $\tilde{\nu}_{max}$  = 3350, 2927, 2857, 1653, 1512, 1482, 1089, 1059 cm<sup>-1</sup>; <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD, 45 °C):  $\delta = 8.52$  (s, 1 H), 8.19 (s, 1 H), 8.08 (s, 1 H), 7.44 (s, 1 H), 6.63 (q, J = 7.0 Hz, 1 H), 6.47, (d, J=1.5 Hz, 1 H), 6.21 (d, J=1.0 Hz, 1 H), 5.98 (br s, 1 H), 5.85 (br s, 1 H), 5.70 (d, J = 1.5 Hz, 1 H), 5.69 (d, J = 1.0 Hz, 1 H), 5.51 (s, 1 H), 5.24 (br d, J=17.0 Hz, 1 H), 5.19 (t, J=9.2 Hz, 1 H), 5.13 (br d, J=11.0 Hz, 1 H), 5.09 (d, J = 4.0 Hz, 1 H), 4.47–4.41 (m, 3 H), 4.19–4.15 (m, 1 H), 4.13 (q, J=7.0 Hz, 1 H), 3.81 (br d, J=10.6 Hz, 1 H), 3.70 (dd, J=9.7, 1.8 Hz, 1 H), 3.48 (dd, J=8.8, 2.6 Hz, 1 H), 2.85 (quintet, J=7.4 Hz, 1 H), 2.62 (dt, J = 8.3, 3.0 Hz, 1 H), 1.82 (d, J = 7.0 Hz, 3 H), 1.32 (d, J = 6.6 Hz, 3 H)3 H), 1.25 (d, J = 7.5 Hz, 3 H), 1.24 (s, 3 H), 1.21 (d, J = 6.6 Hz, 3 H), 1.05 ppm (d, J=6.1 Hz, 3 H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD, 45 °C):  $\delta =$  175.4, 173.8, 171.8, 171.5, 169.9, 168.3, 164.6, 164.2, 163.9, 163.4, 161.2, 153.5, 152.2, 150.7, 149.6, 136.4, 136.1, 136.0, 134.4, 130.9, 125.6, 119.3, 117.9, 107.2, 106.1, 102.5, 88.0, 80.14, 76.9, 71.3, 71.0, 69.8, 69.5, 66.9, 59.4, 58.1, 57.5, 37.5, 36.9, 33.7, 30.8, 30.4, 20.9, 19.8, 19.4, 17.5, 14.5 ppm; HRMS (MALDI): calcd for  $C_{52}H_{61}N_{15}O_{14}S_5$  [*M*+H<sup>+</sup>]: 1280.3199; found: 1280.3184

```
3: R_f = 0.32 (silica gel, CH_2Cl_2/MeOH, 9:1); [\alpha]_D^{20} = +98.5 (c=0.55,
MeOH); IR (film): \tilde{\nu}_{max} = 3375, 2913, 2853, 1658, 1643, 1449, 1249, 1061,
733 cm<sup>-1</sup>; <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD, 45 °C): \delta = 8.51 (s, 1 H), 8.21 (s,
1 H), 8.12 (s, 1 H), 7.34 (br s, 1 H), 6.61 (q, J=7.0 Hz, 1 H), 6.49, (d,
/=1.5 Hz, 1 H), 6.20 (d, /=1.5 Hz, 1 H), 5.86–5.78 (br s, 2 H), 5.71–5.69
(m, 2 H), 5.54 (br s, 1 H), 5.23–5.19 (m, 3 H), 5.09 (b, 1 H). 4.48–4.42 (m,
3 H), 4.38–4.32 (m, 3 H), 4.19–4.16 (m, 1 H), 3.90 (q, J=6.6 Hz, 1 H),
3.65 (t, J=10.7 Hz, 1 H), 3.45 (dd, J=8.8, 2.2 Hz, 1 H), 3.21-3.18 (m,
1 H), 2.59 (dt, J = 8.3, 3.1 Hz, 1 H), 1.80 (d, J = 7.0 Hz, 3 H), 1.39 (s, 3 H),
1.33-1.31 (m, 6H), 1.24-1.22 ppm (m, 6H); <sup>13</sup>C NMR (150 MHz,
CD<sub>3</sub>OD, 45 °C): δ = 175.3, 174.8, 174.0, 173.6, 172.0, 171.7, 170.9, 168.3,
164.6, 164.2, 163.7, 161.2, 152.2, 150.6, 149.9, 136.6, 136.4, 136.2, 130.8,
130.2, 119.1, 117.9, 107.3, 106.0, 87.8, 80.1, 76.8, 70.7, 69.8, 69.2, 66.8,
60.2, 59.1, 58.1, 58.0, 37.2, 37.0, 26.4, 20.7, 20.6, 19.5, 18.7, 17.6,
14.6 ppm; HRMS (MALDI): calcd for C<sub>52</sub>H<sub>61</sub>N<sub>15</sub>O<sub>14</sub>S<sub>5</sub> [M+H<sup>+</sup>]:
1280.3199; found: 1280.3197
```

Within the described chemistry may lie clues for both the successful total synthesis of thiostrepton (1) and the design of bioactive analogues of this intriguing natural product.

Received: April 24, 2003 [Z51745]

**Keywords:** amino acids · antibiotics · macrocycles · natural products · thiazolines

 Isolation: a) J. F. Pagano, M. J. Weinstein, H. A. Stout, R. Donovick, Antibiot. Annu. 1955–1956, 554–559; b) J. Vandeputte, J. D. Dutcher, Antibiot. Annu. 1955–1956, 560–561;
c) B. A. Steinberg, W. P. Jambor, L. O. Suydam, Antibiot. Annu. 1955–1956, 562–565; structure determination: d) C. S. Bond, M. P. Shaw, M. S. Alphey, W. N. Hunter, Acta Crystallogr. Sect. D 2001, D57, 755–758; e) B. Anderson, D. C. Hodgkin, M. A. Viswamitra, Nature 1970, 225, 233–235.

- [2] K. C. Nicolaou, M. Nevalainen, B. S. Safina, M. Zak, S. Bulat, Angew. Chem. 2002, 114, 2021–2025; Angew. Chem. Int. Ed. 2002, 41, 1941–1945.
- [3] K. C. Nicolaou, B. S. Safina, C. Funke, M. Zak, F. J. Zécri, Angew. Chem. 2002, 114, 2017–2020; Angew. Chem. Int. Ed. 2002, 41, 1937–1940.
- [4] S. Higashibayashi, K. Hashimoto, M. Nakata, *Tetrahedron Lett.* 2002, 43, 105–110.
- [5] J. M. Torres-Valencia, C. M. Cerda-García-Rojas, P. Joseph-Nathan, *Tetrahedron: Asymmetry* 1998, 9, 757–764.
- [6] S. Kobayashi, H. Ishitani, M. Ueno, Synlett 1997, 115-116.
- [7] C. Cativiela, M. D. Díaz-de-Villegas, J. A. Gálvez, *Tetrahedron Lett.* **1995**, *36*, 2859–2860.
- [8] C. Holzapfel, G. J. Pettit, J. Org. Chem. 1985, 50, 2323-2327.
- [9] a) P. T. Nyffeler, C.-H. Liang, K. M. Koeller, C.-H. Wong, J. Am. Chem. Soc. 2002, 124, 10773–10778; b) P. B. Alper, S.-C. Hung, C.-H. Wong, Tetrahedron Lett. 1996, 37, 6029–6032.
- [10] J. C. Muir, G. Pattenden, R. M. Thomas, Synthesis 1998, 613-618.
- [11] P. Lafargue, P. Guenot, J.-P. Lellouche, Synlett 1995, 171-172.
- [12] F. Bravo, Y. Díaz, S. Castillón, *Tetrahedron: Asymmetry* 2001, 12, 1635–1643.
- [13] N. M. Okeley, Y. Zhu, W. A. van der Donk, Org. Lett. 2000, 2, 3603–3606.
- [14] Thiazolines are readily epimerizable substrates, see, for instance:P. Wipf, P. C. Fritch, *Tetrahedron Lett.* **1994**, *35*, 5397–5400.
- [15] Although transesterifications from methyl esters to tin esters with Me<sub>3</sub>SnOH are known (for a review, see: O. A. Mascaretti, R. L. E. Furlan, C. J. Salomon, E. G. Mata, *Phosphorus Sulfur Silicon Relat. Elem.* **1999**, *150–151*, 89–97), only one application of this method has been reported dealing with the cleavage of benzyl esters: R. L. E. Furlan, E. G. Mata, O. A. Mascaretti, C. Pena, M. P. Coba, *Tetrahedron* **1998**, *54*, 13023–13034.
- [16] The corresponding Z-conjugated thiazole system of micrococcin P<sub>1</sub> was prepared by stereospecific elimination of the activated hydroxy group: a) F. Yokokawa, T. Shioiri, *Tetrahedron Lett.* 2002, 43, 8679–8682; b) M. A. Ciufolini, Y.-C. Shen, Org. *Lett.* 1999, 1, 1843–1846.
- [17] P. M. T. Ferreira, H. L. S. Maia, L. S. Monteiro, J. Sacramento, J. Chem. Soc. Perkin Trans. 1 1999, 3697–3703.
- [18] Minimum inhibitory concentration (MIC) assays were performed with the following bacteria: methicillin-resistant *Staphylococcus aureus* (MRSA) (ATCC 33591), vancomycin-resistant *Enterococcus faecium* (VRE) (ATCC 700221), *Pseudomonas aeruginosa* (PA) (27853), *Escherichia coli* (EC1) (ATCC 700336), *Escherichia coli* (EC2) (ATCC 29425). We thank Dr. J. Fletcher and Dr. R. Ghadiri for these experiments.